Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic

被引:3
|
作者
Sano, Hiroyuki [1 ]
Imagawa, Akihisa [1 ]
机构
[1] Osaka Med & Pharmaceut Univ, Dept Internal Med 1, Takatsuki 5698686, Japan
来源
BIOLOGY-BASEL | 2022年 / 11卷 / 11期
关键词
fulminant type 1 diabetes; autoimmune type 1 diabetes; coronavirus disease 2019; severe acute respiratory syndrome coronavirus-2; enterovirus; innate immunity; acquired immunity; ENCEPHALOMYOCARDITIS-VIRUS; NATIONWIDE SURVEY; ACUTE-ONSET; AUTOIMMUNE PANCREATITIS; INSULIN-SECRETION; ADULT-ONSET; BETA-CELLS; PD-1; GENE; T-CELLS; MELLITUS;
D O I
10.3390/biology11111662
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Simple Summary From 2019, coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread worldwide and became a serious problem. It is known that various viruses are involved in the development of type 1 diabetes (T1D), but the reports of an association between SARS-CoV-2 and T1D are mixed. Fulminant type 1 diabetes (FT1D) is a subtype of T1D mainly reported from East Asia. Autoimmune type 1 diabetes (AT1D) is characterized by chronic pancreatic beta-cell destruction, whereas FT1D is characterized by rapid and almost complete islet destruction following flu-like symptoms, leading to ketoacidosis and, in some cases, sudden death. When discussing the association between COVID-19 and T1D, it is also necessary to focus on FT1D. However, it is not easy to diagnose this subtype without understanding the concept. Therefore, the authors hereby review the concept and latest findings, hoping that the association between COVID-19 and T1D will be adequately evaluated in the future. Fulminant type 1 diabetes (FT1D) is a subtype of type 1 diabetes (T1D) that is characterized by the rapid progression to diabetic ketoacidosis against the background of rapid and almost complete pancreatic islet destruction. The HbA1c level at FT1D onset remains normal or slightly elevated despite marked hyperglycemia, reflecting the rapid clinical course of the disease, and is an important marker for diagnosis. FT1D often appears following flu-like symptoms, and there are many reports of its onset being linked to viral infections. In addition, disease-susceptibility genes have been identified in FT1D, suggesting the involvement of host factors in disease development. In most cases, islet-related autoantibodies are not detected, and histology of pancreatic tissue reveals macrophage and T cell infiltration of the islets in the early stages of FT1D, suggesting that islet destruction occurs via an immune response different from that occurring in autoimmune type 1 diabetes. From 2019, coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread worldwide and became a serious problem. Reports on the association between SARS-CoV-2 and T1D are mixed, with some suggesting an increase in T1D incidence due to the COVID-19 pandemic. When discussing the association between COVID-19 and T1D, it is also necessary to focus on FT1D. However, it is not easy to diagnose this subtype without understanding the concept. Therefore, authors hereby review the concept and the latest findings of FT1D, hoping that the association between COVID-19 and T1D will be adequately evaluated in the future.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Fulminant type 1 diabetes after COVID-19 vaccination
    Tang, Xiaohan
    He, Binbin
    Liu, Zhenqi
    Zhou, Zhiguang
    Li, Xia
    [J]. DIABETES & METABOLISM, 2022, 48 (02)
  • [2] Effects of the COVID-19 Pandemic on Type 1 Diabetes Outcomes
    Geiser, Luke
    Pyle, Laura
    Vigers, Timothy B.
    Meltzer, Lisa J.
    Cobry, Erin C.
    [J]. DIABETES, 2022, 71
  • [3] Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak?
    Caruso, Paola
    Longo, Miriam
    Esposito, Katherine
    Maiorino, Maria Ida
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 164
  • [4] The impact of covid-19 pandemic on the incidence type 1 diabetes in children
    Kurmacheva, Nataliia
    Svinarev, Michail
    Chernenkov, Yuriy
    Gumeniuk, Olga
    Aranovich, Vera
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 193 - 193
  • [5] TELEASSISTANCE IN PATIENTS WITH TYPE 1 DIABETES DURING COVID-19 PANDEMIC
    Cutruzzola, A.
    Parise, M.
    Tartaglione, L.
    Maiorino, M. I.
    Esposito, K.
    Pitocco, D.
    Gnasso, A.
    Irace, C.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A129 - A130
  • [6] Children with type 1 diabetes in COVID-19 pandemic: Difficulties and solutions
    Yue Shi
    Li-Qun Wu
    Peng Wei
    Ze-Huan Liao
    [J]. World Journal of Clinical Pediatrics, 2022, 11 (05) : 408 - 418
  • [7] Features of the manifestation of type 1 diabetes in children in COVID-19 pandemic
    Rudkova, Ekaterina
    Solntsava, Anzhalika
    Grisuk, Ivan
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 243 - 243
  • [8] Effect of COVID-19 pandemic on treatment of Type 1 diabetes in children
    Ludvigsson, Johnny
    [J]. ACTA PAEDIATRICA, 2021, 110 (03) : 933 - 934
  • [9] Glycemic control in type 1 diabetes during COVID-19 pandemic
    Secco, Katharina
    Ziko, Haris
    Poettler, Tina
    Hochfellner, Daniel
    Weitgasser, Raimund
    Schuetz-Fuhrmann, Ingrid
    Mader, Julia Katharina
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (SUPPL 6) : 220 - 220
  • [10] Improved glucometrics in people with type 1 diabetes 1 year into the COVID-19 pandemicImproved glucometrics in people with type 1 diabetes 1 year into the COVID-19 pandemic
    Ali, Namam
    El Hamdaoui, Soumia
    Nefs, Giesje
    Tack, Cornelis J.
    De Galan, Bastiaan E.
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (03)